42.20
-0.35 (-0.82%)
| Previous Close | 42.55 |
| Open | 42.65 |
| Volume | 9,108,495 |
| Avg. Volume (3M) | 11,816,168 |
| Market Cap | 16,488,960,000 |
| Price / Sales | 8.25 |
| Price / Book | 1.96 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2026 |
| Profit Margin | -105.67% |
| Operating Margin (TTM) | -972.22% |
| Diluted EPS (TTM) | -8.73 |
| Quarterly Revenue Growth (YOY) | -35.30% |
| Total Debt/Equity (MRQ) | 7.40% |
| Current Ratio (MRQ) | 4.22 |
| Operating Cash Flow (TTM) | -3.05 B |
| Levered Free Cash Flow (TTM) | -3.20 B |
| Return on Assets (TTM) | -15.84% |
| Return on Equity (TTM) | -29.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Moderna, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.5 |
| Average | -0.38 |
|
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.28% |
| % Held by Institutions | 73.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Theleme Partners Llp | 30 Sep 2025 | 8,068,810 |
| Flagship Pioneering, Llc | 30 Sep 2025 | 4,632,149 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 63.00 (Piper Sandler, 49.29%) | Buy |
| Median | 26.50 (-37.20%) | |
| Low | 18.00 (Leerink Partners, -57.35%) | Sell |
| Average | 30.50 (-27.73%) | |
| Total | 1 Buy, 5 Hold, 2 Sell | |
| Avg. Price @ Call | 26.91 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 07 Jan 2026 | 34.00 (-19.43%) | Hold | 35.89 |
| Jefferies | 12 Dec 2025 | 30.00 (-28.91%) | Hold | 29.46 |
| Morgan Stanley | 12 Dec 2025 | 28.00 (-33.65%) | Hold | 29.46 |
| Leerink Partners | 21 Nov 2025 | 18.00 (-57.35%) | Sell | 23.72 |
| Piper Sandler | 21 Nov 2025 | 63.00 (49.29%) | Buy | 23.72 |
| RBC Capital | 21 Nov 2025 | 25.00 (-40.76%) | Hold | 23.72 |
| B of A Securities | 10 Nov 2025 | 21.00 (-50.24%) | Sell | 24.76 |
| Barclays | 07 Nov 2025 | 25.00 (-40.76%) | Hold | 24.54 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |